Source:http://linkedlifedata.com/resource/pubmed/id/21123160
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2010-12-2
|
pubmed:abstractText |
The aim of this observational prospective study was to compare the effect of fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in the treatment of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli-related complicated lower urinary tract infection (CLUTI). Inclusion criteria were: patients who were aged >18 yr with dysuria or problems with frequency or urgency in passing urine; those with >20 leukocytes/mm³ in urine microscopy and culture-proven ESBL-producing carbapenem or FT-sensitive E. coli in the urine (>10? cfu/mm³); no leukocytosis or fever; and who were treated with ft (oral 3 g sachet x 1 every other night, three times) or carbapenems between march 2005 and January 2006 in our outpatient clinic and hospital. A total of 47 CLUTI attacks in 47 patients (27 FT group, 20 carbapenem group) were observed prospectively. Clinical and microbiological success in the carbapenem and ft groups was similar (19/20 vs 21/27 and 16/20 vs 16/27 p>0.05). Drug acquisition costs were significantly lower in the FT group (p<0.001). Although it is not a randomized controlled study, these data show that ft may be a suitable, effective and cheap alternative in the treatment of ESBL-producing E. coli-related CLUTI.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1973-9478
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
22
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
355-7
|
pubmed:meshHeading |
pubmed-meshheading:21123160-Adult,
pubmed-meshheading:21123160-Aged,
pubmed-meshheading:21123160-Aged, 80 and over,
pubmed-meshheading:21123160-Anti-Bacterial Agents,
pubmed-meshheading:21123160-Carbapenems,
pubmed-meshheading:21123160-Drug Resistance, Bacterial,
pubmed-meshheading:21123160-Escherichia coli,
pubmed-meshheading:21123160-Escherichia coli Infections,
pubmed-meshheading:21123160-Female,
pubmed-meshheading:21123160-Fosfomycin,
pubmed-meshheading:21123160-Humans,
pubmed-meshheading:21123160-Male,
pubmed-meshheading:21123160-Microbial Sensitivity Tests,
pubmed-meshheading:21123160-Middle Aged,
pubmed-meshheading:21123160-Prospective Studies,
pubmed-meshheading:21123160-Urinary Tract Infections,
pubmed-meshheading:21123160-Young Adult,
pubmed-meshheading:21123160-beta-Lactamases
|
pubmed:year |
2010
|
pubmed:articleTitle |
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
|
pubmed:affiliation |
Celal Bayar University, Department of Infectious Diseases and Clinical Microbiology, Manisa, Turkey.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|